SEATTLE, Wash. – April 19, 2013 – Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company’s precision oncology platform designed to improve treatment decisions for cancer patients. The single arm, non-therapeutic, observational study, being conducted at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, is intended to evaluate the feasibility of Presage’s CIVO in assessing lymphoma response to multiple microinjected candidate chemotherapy agents.
SEATTLE, Wash. – March 5, 2013 – Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which Presage and Celgene will take advantage of Presage’s proprietary technology platform to identify novel drug combinations for solid tumor indications.
Presage Biosciences and Millennium Pharmaceuticals Enter Into Cancer Research Agreement
SEATTLE, Wash. and CAMBRIDGE, Mass. – April 5, 2012 – Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company. The research agreement will provide Millennium with access to Presage’s proprietary technology platform to enable non-clinical identification of effective novel oncology drug combinations in solid tumors.
Biosciences Appoints Jim Towne as CEO
SEATTLE– December 15, 2011 – Presage Biosciences, a privately held biotechnology company that works with oncology-focused pharmaceutical companies through strategic alliances using it’s patented three-dimensional in vivo drug analysis platform, announced
today that Caitlin Cameron has resigned as the CEO and director of Presage effective December 31, 2011. Jim Towne, a Presage Board member, was named as interim CEO. Ms. Cameron will continue to work closely with Presage leadership as an advisor.